Why Big Pharma must disclose payments to patient groups
Evidence shows that opioid manufacturers fund patient advocacy groups in Canada, distorting policies to protect public health.
Evidence shows that opioid manufacturers fund patient advocacy groups in Canada, distorting policies to protect public health.
Research shows that THC and CBD in cannabis have potential to interrupt the vicious cycle of opioid addiction, dependence, withdrawal and relapse.
Most physicians are unaware of effective approaches to treat opioid addiction. Addiction medicine fellowships offer a new and effective way to save lives.
Opioids kill an average of eight people every day in Canada. The federal government must officially declare this a ‘public welfare emergency’ and invest the funds critical to a humane response.
One in five Canadians suffers chronic pain and almost 2,500 died last year from opioid overdose. A National Pain Strategy promises to tackle both problems.
Unlike opium, nitazenes and other synthetic opioids can be produced anywhere in the world using precursor chemicals that are often uncontrolled.
As Canada moves towards legalization of cannabis in 2018, there is growing evidence of the drug’s potential to treat opioid addiction itself, as well as the chronic pain that often drives it.
Cannabis legalization in Canada is a public health strategy. Let’s harness this opportunity to understand how cannabis could fit into a multi-faceted opioid prevention and response strategy.
Catastrophic increases in opioid overdose deaths across Canada require a broad response – tackling housing, food and income insecurity as well as the contaminated drug supply.
Urgently needed treatment for opioid use disorder is often denied to incarcerated people, feeding the crisis in prisons and jails.